Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vodafone Group PLC

11.87
-0.0500-0.42%
Post-market: 11.75-0.1200-1.01%19:33 EDT
Volume:3.09M
Turnover:36.70M
Market Cap:28.85B
PE:-6.89
High:11.93
Open:11.92
Low:11.86
Close:11.92
52wk High:11.99
52wk Low:8.00
Shares:2.43B
Float Shares:1.98B
Volume Ratio:0.70
T/O Rate:0.16%
Dividend:0.50
Dividend Rate:4.20%
EPS(TTM):-1.7233
EPS(LYR):-1.7232
ROE:-6.48%
ROA:1.55%
PB:0.47
PE(LYR):-6.89

Loading ...

Vodafone Group Rallies Thursday, Outperforms Market

Dow Jones
·
May 16

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
·
May 15

AST SpaceMobile Sets $75 Million Target For 2025 As CFO Andrew Johnson Says 'Revenue Is Ramping On Plan' Amid Surging Demand For Direct-To-Device Satellite Connectivity

Benzinga
·
May 13

Vodafone price target raised to 70 GBp from 66 GBp at Citi

TIPRANKS
·
May 08

Vodafone Group Slides Wednesday, Underperforms Market

Dow Jones
·
May 08

Vodafone Chief Financial Officer Luka Mucic to Step Down

MT Newswires Live
·
May 07

Vodafone's Results to Focus on German Operations, U.K. Merger -- Market Talk

Dow Jones
·
May 07

Citi Remains a Hold on Vodafone (VOD)

TIPRANKS
·
May 07

European Equities Traded in the US as American Depositary Receipts Jump in Friday Trading

MT Newswires Live
·
May 02

Vodafone Group Climbs Wednesday, Outperforms Market

Dow Jones
·
May 01

Vodafone, Fortinet Expand Global Cybersecurity Partnership

MT Newswires Live
·
Apr 29

Vodafone, ServiceNow collaborate over AI-powered service automation

TIPRANKS
·
Apr 24

Vodafone Shares Fall After Downgrade From J.P. Morgan

MT Newswires Live
·
Apr 24

Vodafone Group Slips Wednesday, Underperforms Market

Dow Jones
·
Apr 24

Vodafone Cut to Underweight From Neutral by JP Morgan

Dow Jones
·
Apr 23

J.P. Morgan downgrades Vodafone (VOD) to a Sell

TIPRANKS
·
Apr 23

Vodafone Group Climbs Tuesday, Outperforms Market

Dow Jones
·
Apr 23

Vodafone put volume heavy and directionally bearish

TIPRANKS
·
Apr 22

Vodafone Group Advances Monday, Outperforms Market

Dow Jones
·
Apr 15

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1

Business Wire
·
Apr 09